Usefulness of the GenMark ePlex RPP assay for the detection of respiratory viruses in comparison with the FTD21 multiplex RT-PCR
Cartridge-based multiplex panels overlaying quite a few pathogens provide a bonus of minimal hands-on-time and quick time to consequence to business RT-PCR assays. On this research, we evaluated the efficiency of the ePlex respiratory pathogen panel (RPP) in comparison with the Quick Monitor Diagnostics Respiratory pathogens 21 multiplex RT-PCR assay (FTD21) utilizing 400 medical respiratory samples. Discrepant outcomes had been additional analysed by a reference nucleic acid amplification testing (NAT) and a composite reference method was used for ultimate interpretation. Discordant outcomes had been noticed in 56 targets equivalent to 54 samples. Sensitivities and specificities had been 85.5% and 99.9% for the ePlex RPP and 95.8% and 99.7% for the FTD21 system, respectively. Altogether, the ePlex RPP is a worthwhile device for the speedy detection of quite a lot of completely different respiratory viruses apart from the coronavirus household (low sensitivity starting from 50-80%) and samples with a low pathogen load (Ct values >33).
Type I Diabetes Serum, Human Donor |
|||
MBS170481-1Sample | MyBiosource | 1Sample | EUR 310 |
Type I Diabetes Serum, Human Donor |
|||
MBS170481-5Samples | MyBiosource | 5Samples | EUR 960 |
Type I Diabetes Serum, Human Donor |
|||
MBS170481-5x5Samples | MyBiosource | 5x5Samples | EUR 4110 |
Plasma - Type I Diabetes - Patient Sample |
|||
MBS170490-1Sample | MyBiosource | 1Sample | EUR 310 |
Plasma - Type I Diabetes - Patient Sample |
|||
MBS170490-5Samples | MyBiosource | 5Samples | EUR 1005 |
Plasma - Type I Diabetes - Patient Sample |
|||
MBS170490-5x5Samples | MyBiosource | 5x5Samples | EUR 4310 |
Human Muscle Myoblasts, Diabetes Type I |
|||
ABC-TC3956 | AcceGen | 1 vial | Ask for price |
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
Single Donor Human Type I Diabetes Urine |
|||
IRHUURESDIBTI250ML | Innovative research | each | EUR 1063 |
Description: Single Donor Human Type I Diabetes Urine |
Single Donor Human Type I Diabetes Urine |
|||
IRHUURESDIBTI50ML | Innovative research | each | EUR 439 |
Description: Single Donor Human Type I Diabetes Urine |
Single Donor Human Type I Diabetes Urine |
|||
MBS8421330-250mL | MyBiosource | 250mL | EUR 1285 |
Single Donor Human Type I Diabetes Urine |
|||
MBS8421330-50mL | MyBiosource | 50mL | EUR 595 |
Single Donor Human Type I Diabetes Urine |
|||
MBS8421330-5x250mL | MyBiosource | 5x250mL | EUR 5540 |
Whole Blood - Type I Diabetes - Patient Sample |
|||
MBS170486-1Sample | MyBiosource | 1Sample | EUR 310 |
Whole Blood - Type I Diabetes - Patient Sample |
|||
MBS170486-5x1Sample | MyBiosource | 5x1Sample | EUR 4310 |
Preadipocytes, visc 1M cells, Diabetes Type I |
|||
LOPT-5023 | Westburg | each | EUR 1155.54 |
Preadipocytes, subcu 1M cells, Diabetes Type I |
|||
LOPT-5021 | Westburg | each | EUR 782.64 |
Diabetes (Type 1) Exosome |
|||
P141-DB1 | 101Bio | - | Ask for price |
Diabetes (Type 2) Exosome |
|||
P141-DB2 | 101Bio | - | Ask for price |
Human Type 2 Diabetes PB |
|||
ABC-TC4312 | AcceGen | 1 pack | Ask for price |
Description: Non-RI dependent diabetes, or Type 2 Diabetes, is characterized by hyperglycemia that is caused by a combination of RI resistance and the body's inability to compensate by producing more RI. |
Human Type 1 Diabetes Leukopak |
|||
ABC-TC4310 | AcceGen | 1 pack | Ask for price |
Description: RI dependent diabetes, or Type 1 Diabetes is caused by the pancreas producing little to no RI. |
Human Type 2 Diabetes Leukopak |
|||
ABC-TC4311 | AcceGen | 1 pack | Ask for price |
Description: Non-RI dependent diabetes, or Type 2 Diabetes, is characterized by hyperglycemia that is caused by a combination of RI resistance and the body's s inability to compensate by producing more RI. |
Human Type I Diabetes Peripheral Blood Mononuclear Cells |
|||
ABC-TC4263 | AcceGen | 1 vial | Ask for price |
Description: Peripheral blood mononuclear cells are isolated from Type I Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type I PBMCs is available upon request. |
Diabetes (Type 1) Exosome RNA |
|||
P241-DB1 | 101Bio | - | Ask for price |
Diabetes (Type 2) Exosome RNA |
|||
P241-DB2 | 101Bio | - | Ask for price |
D-Adipose-Derived stem cells, human, Type I Diabetes |
|||
LOPT-5007 | Westburg | each | EUR 748.19 |
Human Type II Diabetes PB Plasma |
|||
ABC-TC4266 | AcceGen | 1 vial | Ask for price |
Description: Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type II PB plasma is available upon request. |
Type II Diabetes Serum, Human Donor |
|||
MBS170482-1Sample | MyBiosource | 1Sample | EUR 310 |
Type II Diabetes Serum, Human Donor |
|||
MBS170482-5Samples | MyBiosource | 5Samples | EUR 960 |
Type II Diabetes Serum, Human Donor |
|||
MBS170482-5x5Samples | MyBiosource | 5x5Samples | EUR 4110 |
Plasma - Type II Diabetes - Human Patient |
|||
MBS170491-1Sample | MyBiosource | 1Sample | EUR 310 |
Plasma - Type II Diabetes - Human Patient |
|||
MBS170491-5Samples | MyBiosource | 5Samples | EUR 1005 |
Plasma - Type II Diabetes - Human Patient |
|||
MBS170491-5x5Samples | MyBiosource | 5x5Samples | EUR 4310 |
Human iPS Cell Line (Type 2 Diabetes) |
|||
CSC-00849L | Creative Bioarray | One Frozen vial | Ask for price |
D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type I |
|||
LOCC-2919 | Westburg | each | EUR 1920.94 |
Single Donor Human Type II Diabetes Urine |
|||
IRHUURESDIBTII250ML | Innovative research | each | EUR 1063 |
Description: Single Donor Human Type II Diabetes Urine |
Single Donor Human Type II Diabetes Urine |
|||
IRHUURESDIBTII50ML | Innovative research | each | EUR 439 |
Description: Single Donor Human Type II Diabetes Urine |
Single Donor Human Type II Diabetes Urine |
|||
MBS8421331-250mL | MyBiosource | 250mL | EUR 1285 |
Single Donor Human Type II Diabetes Urine |
|||
MBS8421331-50mL | MyBiosource | 50mL | EUR 595 |
Single Donor Human Type II Diabetes Urine |
|||
MBS8421331-5x250mL | MyBiosource | 5x250mL | EUR 5540 |
Human Muscle Myoblasts, Diabetes Type II |
|||
ABC-TC3957 | AcceGen | 1 vial | Ask for price |
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
Whole Blood - Type II Diabetes - Patient Sample |
|||
MBS170487-1Sample | MyBiosource | 1Sample | EUR 310 |
Whole Blood - Type II Diabetes - Patient Sample |
|||
MBS170487-5x1Sample | MyBiosource | 5x1Sample | EUR 4310 |
D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type I |
|||
LOCC-2914 | Westburg | each | EUR 1888.07 |
HighQC™ Human IPS Cell (Type 2 Diabetes) |
|||
ABC-SC0005T | AcceGen | 1 vial | Ask for price |
Description: Induced Pluriopotent Stem Cells (iPSCs) are a type of pluripotent stem cells that can be derived directly from adult somatic cells . The derived iPSCs can propagate indefinitely, as well as give rise to other cell types in the body. iPS cells, thus, hold great promise in the field of regenerative medicine by representing a single source of cells that could be used to replace those damaged/diseased cells. |
Preadipocytes, visc 1M cells, Diabetes Type II |
|||
LOPT-5024 | Westburg | each | EUR 1155.54 |
Preadipocytes, subcu 1M cells, Diabetes Type II |
|||
LOPT-5022 | Westburg | each | EUR 782.64 |
D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type I |
|||
LOCC-2917 | Westburg | each | EUR 1880.03 |
D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type I |
|||
LOCC-2927 | Westburg | each | EUR 1299.42 |
D-HCAEC – Diseased Human Coronary Artery Endothelial Cells – Diabetes Type I |
|||
LOCC-2921 | Westburg | each | EUR 1884.64 |
Human Type II Diabetes Peripheral Blood Mononuclear Cells |
|||
ABC-TC4265 | AcceGen | 1 vial | Ask for price |
Description: Human Peripheral Blood Mononuclear Cells are available as positive and negative controls for T-cell monitoring in ELISPOT, ELISA, cytokine bead array, tetramer/pentamer, and flow cytometry assays. A peripheral blood mononuclear cell is defined as any blood cell with a round nucleus. These blood cells are a critical component in the immune system to fight infection and adapt to intruders. The lymphocyte population consists of CD4+ and CD8+ T cells, B cells and Natural Killer cells, CD14+ Monocytes, and Basophils/Neutrophils/Eosinophils/Dendritic cells. These cells are often extracted from whole blood or from leukopacks using ficoll, a hydrophilic polysaccharide that separates layers of blood, with monocytes and lymphocytes forming a buffy coat under a layer of plasma.Samples from each donor are tested via PCR to confirm non-reactivity. Peripheral blood mononuclear cells are isolated from Type II Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type II PBMCs is available upon request. |
D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type I |
|||
LOCC-2923 | Westburg | each | EUR 1920.94 |
D-Adipose-Derived stem cells, human, Type II Diabetes |
|||
LOPT-5008 | Westburg | each | EUR 748.19 |
D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type I |
|||
LOCC-2915 | Westburg | each | Ask for price |
D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type I |
|||
LOCC-2929 | Westburg | each | EUR 1169.49 |
D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type II |
|||
LOCC-2920 | Westburg | each | EUR 1920.94 |
HighQC™ Human IPS Cell (Episomal/ Diabetes Type II/ Adipose) |
|||
ABC-SC0011T | AcceGen | 1 vial | Ask for price |
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type II |
|||
LOCC-2916 | Westburg | each | Ask for price |
HighQC™ Human IPS Cell (IPSC From PBMC/ Diabetes Type II/ Episomal) |
|||
ABC-SC0009T | AcceGen | 1 vial | Ask for price |
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
D-HCAEC – Diseased Human Coronary Artery Endothelial – Diabetes Type II |
|||
LOCC-2922 | Westburg | each | EUR 1884.64 |
D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type II |
|||
LOCC-2918 | Westburg | each | EUR 1880.03 |
HighQC™ Human IPS Cell (IPSC From Fibroblast/ Diabetes Type II/ Episomal) |
|||
ABC-SC0010T | AcceGen | 1 vial | Ask for price |
Description: Gentaur is is proud to offer human iPS cell lines derived from the human dermal fibroblasts from patients with Type 2 Diabetes (T2D). The pertinent donor information is available upon request. These iPS cells are established from a single clone and expanded in feeder-free conditions. Normal human iPS cell lines are also available as separate products . We also provide custom iPSC generation and iPSC differentiation services to meet your needs. |
D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type II |
|||
LOCC-2928 | Westburg | each | Ask for price |
D-HEK-Ad – Diseased Human Adult Epidermal Keratinocytes – Diabetes Type II |
|||
LOCC-2926 | Westburg | each | EUR 841.52 |
D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type II |
|||
LOCC-2924 | Westburg | each | Ask for price |
HighQC™ Human Bone Marrow Derived Mesenchymal Stem Cell/ Type II Diabetes Patient |
|||
ABC-SC0027T | AcceGen | 1 vial | Ask for price |
Description: Human MSCs (Bone Marrow Derived) from a single adult donor clinically diagnosed with Type II Diabetes. The MSCs are compatible with our MSC Expansion Medium for Bone Marrow Derived MSCs.All of the cells provided are tested and are negative for HIV-1, HIV-2, Hepatitis B and Hepatitis C as detected by PCR. The cells are confirmed to be negative for mycoplasma and other detectable microbial contamination. |
D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type II |
|||
LOCC-2913 | Westburg | each | EUR 1935.75 |
D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type II |
|||
LOCC-2930 | Westburg | each | Ask for price |
Linearity FD Special Diabetes |
|||
K889M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
D-RPTEC – Diseased Human Renal Proximal Tubule Epithelial Cells – Diabetes Type II |
|||
LOCC-2925 | Westburg | each | EUR 2091.71 |
Human Diabetes Lung Tissue Lysate |
|||
IHULGDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Lung Tissue Lysate |
Single Donor Human Diabetes Serum |
|||
ISERSDIB | Innovative research | each | EUR 209 |
Description: Single Donor Human Diabetes Serum |
Single Donor Human Diabetes Serum |
|||
MBS8421607-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes Lung Tissue Lysate |
|||
MBS8414460-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Lung Tissue Lysate |
|||
MBS8414460-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Ileum Tissue Lysate |
|||
IHUILMDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Ileum Tissue Lysate |
Human Diabetes Colon Tissue Lysate |
|||
IHUCLNDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Colon Tissue Lysate |
Single Donor Human Diabetes Plasma |
|||
IPLASDIB | Innovative research | each | EUR 209 |
Description: Single Donor Human Diabetes Plasma |
Human Diabetes Colon Tissue Lysate |
|||
MBS139594-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Colon Tissue Lysate |
|||
MBS139594-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Ileum Tissue Lysate |
|||
MBS8413586-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Ileum Tissue Lysate |
|||
MBS8413586-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Single Donor Human Diabetes Plasma |
|||
MBS8421060-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes Jejunum Tissue Lysate |
|||
IHUJEJDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Jejunum Tissue Lysate |
Human Diabetes Stomach Tissue Lysate |
|||
IHUSTDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Stomach Tissue Lysate |
Human Diabetes Jejunum Tissue Lysate |
|||
MBS8413808-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Jejunum Tissue Lysate |
|||
MBS8413808-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Stomach Tissue Lysate |
|||
MBS8420033-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Stomach Tissue Lysate |
|||
MBS8420033-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Duodenum Tissue Lysate |
|||
IHUDUODIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Duodenum Tissue Lysate |
Human Diabetes Pancreas Tissue Lysate |
|||
IHUPCSDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Pancreas Tissue Lysate |
Human Diabetes Pancreas Tissue Lysate |
|||
MBS8416917-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Pancreas Tissue Lysate |
|||
MBS8416917-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Duodenum Tissue Lysate |
|||
MBS8410767-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Duodenum Tissue Lysate |
|||
MBS8410767-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Esophagus Tissue Lysate |
|||
IHUESOPDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Esophagus Tissue Lysate |
Human Diabetes Esophagus Tissue Lysate |
|||
MBS8411234-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Esophagus Tissue Lysate |
|||
MBS8411234-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
IHUADPTVDIBTL100UG | Innovative research | each | EUR 2663 |
Description: Human Diabetes AdiposeVisceral Tissue Lysate |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
MBS136954-01mg | MyBiosource | 0.1mg | EUR 3320 |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
MBS136954-5x01mg | MyBiosource | 5x0.1mg | EUR 14765 |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
IHUSKMDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Skeletal Muscle Tissue Lysate |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
MBS8419496-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
MBS8419496-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
IHUADPTSDIBTL100UG | Innovative research | each | EUR 2663 |
Description: Human Diabetes AdiposeSubcutaneous Tissue Lysate |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
MBS136950-01mg | MyBiosource | 0.1mg | EUR 3320 |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
MBS136950-5x01mg | MyBiosource | 5x0.1mg | EUR 14765 |
Diabetes Drug Leads Bioactive Peptide Library |
|||
L-012 | PHOENIX PEPTIDE | 160 peptides | EUR 7938 |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
IHUPCSDIBTLM100UG | Innovative research | each | EUR 1199 |
Description: Human Diabetes Pancreas Lysate Membrane Fraction |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
MBS8416918-01mg | MyBiosource | 0.1mg | EUR 1550 |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
MBS8416918-5x01mg | MyBiosource | 5x0.1mg | EUR 6780 |
Linearity FLQ Special Diabetes for Roche Systems |
|||
K929M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
Tissue, Section, Human Disease, Diabetes, Eye (Frozen) |
|||
MBS640656-5Slides | MyBiosource | 5Slides | EUR 930 |
Tissue, Section, Human Disease, Diabetes, Eye (Frozen) |
|||
MBS640656-5x5Slides | MyBiosource | 5x5Slides | EUR 3955 |
Tissue, Total Protein, Human Disease, Diabetes, Lung |
|||
MBS657041-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Lung |
|||
MBS657041-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Skin |
|||
MBS657133-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Skin |
|||
MBS657133-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Linearity FLQ Special Diabetes for Abbott Systems |
|||
K956M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
Tissue, Section, Human Disease, Diabetes, Skin (Frozen) |
|||
MBS640139-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Skin (Frozen) |
|||
MBS640139-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Lung (Frozen) |
|||
MBS640535-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Lung (Frozen) |
|||
MBS640535-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Brain |
|||
MBS657014-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Brain |
|||
MBS657014-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Liver |
|||
MBS657060-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Liver |
|||
MBS657060-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Colon |
|||
MBS657406-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Colon |
|||
MBS657406-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Heart |
|||
MBS657486-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Heart |
|||
MBS657486-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Liver (Frozen) |
|||
MBS640704-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Liver (Frozen) |
|||
MBS640704-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Brain (Frozen) |
|||
MBS640760-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Brain (Frozen) |
|||
MBS640760-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Colon (Frozen) |
|||
MBS640835-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Colon (Frozen) |
|||
MBS640835-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Heart (Frozen) |
|||
MBS640578-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Heart (Frozen) |
|||
MBS640578-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Spleen |
|||
MBS657230-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Spleen |
|||
MBS657230-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Kidney |
|||
MBS657520-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Kidney |
|||
MBS657520-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Kidney (Frozen) |
|||
MBS639978-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Kidney (Frozen) |
|||
MBS639978-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Spleen (Frozen) |
|||
MBS640944-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Spleen (Frozen) |
|||
MBS640944-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Lung (Paraffin) |
|||
MBS640452-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Lung (Paraffin) |
|||
MBS640452-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Total Protein, Human Disease, Diabetes, Adrenal |
|||
MBS657074-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Adrenal |
|||
MBS657074-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Stomach |
|||
MBS657368-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Stomach |
|||
MBS657368-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Adrenal (Frozen) |
|||
MBS640239-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Adrenal (Frozen) |
|||
MBS640239-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Colon (Paraffin) |
|||
MBS640373-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Colon (Paraffin) |
|||
MBS640373-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Liver (Paraffin) |
|||
MBS640786-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Liver (Paraffin) |
|||
MBS640786-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Stomach (Frozen) |
|||
MBS640568-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Stomach (Frozen) |
|||
MBS640568-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Pancreas |
|||
MBS657129-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Pancreas |
|||
MBS657129-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Frozen) |
|||
MBS640252-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Frozen) |
|||
MBS640252-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Esophagus |
|||
MBS657305-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Esophagus |
|||
MBS657305-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Stomach (Paraffin) |
|||
MBS640658-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Stomach (Paraffin) |
|||
MBS640658-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Frozen) |
|||
MBS640725-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Frozen) |
|||
MBS640725-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
IHUSKMDIBTLM100UG | Innovative research | each | EUR 1199 |
Description: Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
Tissue, Membrane Protein, Human Disease, Diabetes, Pancreas |
|||
MBS639798-01mg | MyBiosource | 0.1mg | EUR 695 |
Tissue, Membrane Protein, Human Disease, Diabetes, Pancreas |
|||
MBS639798-5x01mg | MyBiosource | 5x0.1mg | EUR 2915 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Paraffin) |
|||
MBS639953-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Paraffin) |
|||
MBS639953-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
MBS8419497-01mg | MyBiosource | 0.1mg | EUR 1550 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
MBS8419497-5x01mg | MyBiosource | 5x0.1mg | EUR 6780 |
Tissue, Total Protein, Human Disease, Diabetes, Whole Eye |
|||
MBS657222-1mg | MyBiosource | 1mg | EUR 1430 |
Tissue, Total Protein, Human Disease, Diabetes, Whole Eye |
|||
MBS657222-5x1mg | MyBiosource | 5x1mg | EUR 6225 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Paraffin) |
|||
MBS640383-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Paraffin) |
|||
MBS640383-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Total Protein, Human Disease, Diabetes, Bone Marrow |
|||
MBS657533-1mg | MyBiosource | 1mg | EUR 1430 |
Tissue, Total Protein, Human Disease, Diabetes, Bone Marrow |
|||
MBS657533-5x1mg | MyBiosource | 5x1mg | EUR 6225 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Frozen) |
|||
MBS640718-5Slides | MyBiosource | 5Slides | EUR 930 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Frozen) |
|||
MBS640718-5x5Slides | MyBiosource | 5x5Slides | EUR 3955 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Paraffin) |
|||
MBS640435-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Paraffin) |
|||
MBS640435-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Total Protein, Human Disease, Diabetes, Skeletal Muscle |
|||
MBS657193-1mg | MyBiosource | 1mg | EUR 820 |
Mixture of a SARS-CoV-2 IgG Assay and RT-PCR for Improved COVID-19 Analysis
Background: Coronavirus illness 2019 (COVID-19), brought on by extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is mostly recognized by reverse transcription (RT)-PCR or serological assays. The SARS-CoV-2 viral load decreases just a few days after symptom onset. Thus, the RT-PCR sensitivity peaks at three days after symptom onset (roughly 80%). We evaluated the efficiency of the ARCHITECT® SARS-CoV-2 IgG assay (henceforth termed IgG assay; Abbott Laboratories, Lake County, IL, USA), and the mixture of RT-PCR and the IgG assay for COVID-19 analysis.
Strategies: On this retrospective research, 206 samples from 70 COVID-19 instances at two hospitals in Tokyo that had been constructive utilizing RT-PCR had been used to investigate the diagnostic sensitivity. RT-PCR-negative (N=166), COVID-19-unrelated (N=418), and Japanese Pink Cross Society (N=100) samples had been used to guage specificity.
Outcomes: Sensitivity elevated day by day after symptom onset and exceeded 84.4% after 10 days. Specificity ranged from 98.2% to 100% for samples from the three case teams. Seroconversion was confirmed from 9 to 20 days after symptom onset in 18 out of 32 COVID-19 instances with a number of samples and from one other case with a constructive consequence within the IgG assay for the primary accessible pattern.
Conclusions: The mix of RT-PCR and IgG assay improves the robustness of laboratory diagnostics by compensating for the constraints of every technique.
Simultaneous Molecular Detection of Frequent Bacterial Enteropathogens in Youngsters with Diarrhea by Multiplex-PCR Assay
Background: Diarrhea stays a serious risk to kids in low- and middle-income international locations, which is the second explanation for dying amongst kids on the planet. The intention of the current research was to develop and consider a multiplex-PCR assay for direct detection of widespread bacterial enteropathogens in fecal specimens.
Strategies: 100 and three stool specimens had been collected from kids beneath 5 years of age with gastroenteritis throughout a six-month interval in Ilam, Iran. The multiplex PCR assay concurrently detected Shigella spp., Campylobacter jejuni, Enteropathogenic Escherichia coli (EPEC), Enterotoxigenic Escherichia coli (ETEC), and Salmonella enterica in stool samples.
Outcomes: Our outcomes demonstrated that the prevalence of Shigella spp. Campylobacter jejuni, EPEC, ETEC, and Salmonella enterica had been 21.35%, 10.67%, 1.94%, 0.97% and 0%, respectively. As well as, Shigella spp. with Campylobacter jejuni and EPEC with Campylobacter jejuni coinfection had been noticed in pattern 11 (10.67%). The analytical sensitivity of the multiplex PCR assay was estimated to be 0.01 ng/µL of genomic DNA from tradition. The analytical specificity was decided to be 100% through the use of widespread and customary enteropathogenic bacterial strains.
Conclusions: The molecular technique developed within the research was speedy, delicate, and particular for detection of widespread bacterial enteropathogens.
Screening of ZIKA virus an infection amongst dengue-like sickness sufferers with damaging RT-PCR for dengue virus in Punjab – Pakistan
Goal: To detect ZIKV utilizing reverse transcription-polymerase chain response (RT-PCR) amongst medical samples examined damaging for Dengue virus (DENV) by RT-PCR in Punjab, 2016.
Strategies: A descriptive cross-sectional research was carried out for length of two months. Whole of 506 samples had been collected inside seven days from onset of sickness from throughout hospitals of Punjab, Pakistan of which 350 had been chosen merely randomly to check for presence of ZIKV through the use of “Trioplex Actual-Time RT-PCR Assay (Trioplex)”. Cohen’s kappa coefficient (κ) and 95% confidence interval (CI) had been used to evaluate the diploma of concordance between DENV constructive outcomes of non-structural protein 1 (NS1) and IgM solid-phase enzyme immunoassay (ELISA).
Outcomes: No samples had been constructive for any ZIKV, DENV or Chikungunya virus (CHIKV) by Trioplex. Among the many 350 samples, 26 samples had been constructive concordant and the diploma of concordance between NS1- and IgM-ELISA was 13% and κ coefficient was -0.71 (95% CI -0.79, -0.63).
Conclusion: At research time, no samples had been constructive for ZIKV. Strengthening laboratory capability to verify arboviruses for Punjab’s laboratories is warranted. Trioplex RT-PCR has 100% sensitivity so there are nominal probabilities of false damaging outcomes. Establishing syndromic surveillance for Zika and conducting a sero-surveillance survey for Zika in areas with excessive human and Aedes mosquito density are advisable in Punjab.
Repositive RT-PCR take a look at in discharged COVID-19 sufferers throughout medical isolation commentary
Targets: The epidemiological and medical traits of sufferers with coronavirus illness 2019 (COVID-19) have been researched. Nonetheless, the prevalence of repositivity by real-time PCR for extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stays unclear.
Strategies: A retrospective research was carried out involving 599 discharged sufferers with COVID-19 in a single medical centre. The medical options of sufferers throughout their hospitalization and 14-day post-discharge quarantine had been collected.
Outcomes: A complete of 122 sufferers (20.4%) out of 599 sufferers retested constructive after discharge. Particularly, 94 (15.7%) retested constructive inside 24 h of discharge, and one other 28 sufferers (4.7%) had been repositive on day 7 after discharge, though none confirmed any medical symptomatic recurrence. Each repositives and non‑repositives have related patterns of IgG and IgM. Notably, the size of hospitalization of non-repositive sufferers was longer than that of 24-h repositive sufferers and 7-day repositive sufferers. As well as, the size of hospitalization of 24-h repositive sufferers was shorter than that of 7-day repositive sufferers, indicating that the size of hospitalization was additionally a determinant of viral shedding.
Conclusion: Our research supplies additional info for bettering the administration of recovered and discharged sufferers, and additional research must be carried out to elucidate the infectiveness of people with extended or RNA repositivity.